Sailong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 26, 2021 at 02:28 pm IST
Share
Sailong Pharmaceutical Group Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 185.43 million compared to CNY 126.84 million a year ago. Revenue was CNY 185.43 million compared to CNY 126.84 million a year ago. Net income was CNY 11.8 million compared to net loss of CNY 21.57 million a year ago. Basic earnings per share from continuing operations was CNY 0.0671 compared to basic loss per share from continuing operations of CNY 0.1225 a year ago. Diluted earnings per share from continuing operations was CNY 0.0671 compared to diluted loss per share from continuing operations of CNY 0.1225 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
